BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.

ABSTRACT:

Purpose

Despite initial sensitivity to chemotherapy, ovarian cancers (OVCA) often develop drug resistance, which limits patient survival. Using specimens and/or genomic data from 289 patients and a panel of cancer cell lines, we explored genome-wide expression changes that underlie the evolution of OVCA chemoresistance and characterized the BCL2 antagonist of cell death (BAD) apoptosis pathway as a determinant of chemosensitivity and patient survival.

Experimental design

Serial OVCA cell cisplatin treatments were performed in parallel with measurements of genome-wide expression changes. Pathway analysis was carried out on genes associated with increasing cisplatin resistance (EC(50)). BAD-pathway expression and BAD protein phosphorylation were evaluated in patient samples an

SUBMITTER: Marchion DC 

PROVIDER: S-EPMC3186862 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature